| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2803006301021 | 300630102 | DEXDOR C/S.SOL.IN 100MCG/ML BTx25AMPSx2ML | 426.61 | 433.01 | 500.30 |
| 05/2018 | 2803006301069 | 300630106 | DEXDOR C/S.SOL.IN 100MCG/ML BTx4VIALSx10ML (κλεισμένο με γκρι ελαστικό πώμα από βρωμοβουτύλιο με επικάλυψη απο φθοριοπολυμερές omniflex plus) | 344.16 | 349.33 | 407.32 |
For sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting, also used in pain relief; anxiety reduction and analgesia
Dexmedetomidine is a specific and selective alpha-2 adrenoceptor agonist. By binding to the presynaptic alpha-2 adrenoceptors, it inhibits the release if norepinephrine, therefore, terminate the propagation of pain signals. Activation of the postsynaptic alpha-2 adrenoceptors inhibits the sympathetic activity decreases blood pressure and heart rate.
2 hours
A mass balance study demonstrated that after nine days an average of 95% of the radioactivity, following intravenous administration of radiolabeled dexmedetomidine, was recovered in the urine and 4% in the feces. Fractionation of the radioactivity excreted in urine demonstrated that products of N-glucuronidation accounted for approximately 34% of the cumulative urinary excretion. The majority of metabolites are excreted in the urine.
* 118 L
* 39 L/h [Healthy volunteers receiving IV infusion (0.2-0.7 mcg/kg/hr)]